Drugs & Targets Personalis Real-Time Variant Tracker identifies resistance mutations across several hundred clinically relevant hotspots January 23, 2026Vol.52 No.03
News Analysis ACS report trumpets 70% five-year survival for all cancers amid uncertain funding outlook January 16, 2026Vol.52 No.02By Jacquelyn Cobb and Paul Goldberg
Health Equity New Medicaid work requirements could lead to 1.6 million missed cancer screenings over two years January 16, 2026Vol.52 No.02By Sara Willa Ernst
Trials & Tribulations A radiation oncologist’s perspective: Why we need to accelerate early detection strategies for lung cancers January 16, 2026Vol.52 No.02By Kevin King
Cancer Policy FDA releases 10 guiding principles for AI use in drug development January 16, 2026Vol.52 No.02By Sara Willa Ernst
Cancer Policy FDA to increase regulatory flexibility for development of cell and gene therapies January 16, 2026Vol.52 No.02By Jacquelyn Cobb
Cancer Policy OpenAI launches ChatGPT Health to analyze medical records January 16, 2026Vol.52 No.02By Claire Marie Porter
Cancer Policy Federal judge grants preliminary injunction to restore $12M in grants to AAP January 16, 2026Vol.52 No.02By Claire Marie Porter
In Brief The Mark Foundation names 2026 Emerging Leader Award recipients January 16, 2026Vol.52 No.02
